Tag: tablets

NEW DELHI, July 30, 2025 /PRNewswire/ -- According to the latest industry analysis, the Global Online Gaming Market is projected to grow from USD 208.58...

NEW DELHI, July 30, 2025 /PRNewswire/ -- According to the latest industry analysis, the Global Online Gaming Market is projected to grow from USD 208.58...

NEW YORK, July 29, 2025 /PRNewswire/ -- Pop On Smiles®, the company known for transforming smiles with its custom-made veneers, is proud to debut...

Minimalist Design, Always on Dark Mode Help Increase Mental Focus and Clarity KENT, Ohio, July 29, 2025 /PRNewswire/ -- In an era where screens dominate...

HONG KONG, July 25, 2025 /PRNewswire/ -- Infinix today unveiled its latest HOT 60 Series lineup, including the HOT 60 Pro+, HOT 60 Pro, HOT...

HONG KONG, July 25, 2025 /PRNewswire/ -- Infinix today unveiled its latest HOT 60 Series lineup, including the HOT 60 Pro+, HOT 60 Pro, HOT...

Hiawatha, Iowa, July 24, 2025 (GLOBE NEWSWIRE) -- SmartphonesPLUS, an electronics trade-in company headquartered in Hiawatha, Iowa, has announced the expansion of its online trade-in platform designed to facilitate the resale and responsible reuse of personal and business electronics. The company’s latest updates aim to address the growing demand for accessible, environmentally conscious disposal methods for used mobile devices, laptops, tablets, and accessories.

TRAIL Series features three ultra-compact DC-only portable power stations, including the 200, 300 and Plus 300 SEATTLE, July 24, 2025 /CNW/ -- EcoFlow, a leading provider...

TRAIL Series features three ultra-compact DC-only portable power stations, including the 200, 300 and Plus 300 SEATTLE, July 24, 2025 /PRNewswire/ -- EcoFlow, a leading provider...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

Wacom MovinkPad 11 is a breakthrough portable creative pad that redefines what a digital drawing device can be. Unlike entertainment-focused tablets, it's built to...

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

SYDNEY, July 15, 2025 /PRNewswire/ -- Miroma Project Factory (MPF), a leader in digital innovation for health and wellbeing, is proud to announce the...